327163-76-8

Basic information

• Product Name: methyl 3,6-dimethoxy-2-nitrobenzoate
• Synonyms: methyl 3,6-dimethoxy-2-nitrobenzoate
• CAS NO: 327163-76-8
• Molecular Weight: 241.2
• Mol File: 327163-76-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: methyl 3,6-dimethoxy-2-nitrobenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 3,6-dimethoxy-2-nitrobenzoate(327163-76-8)
• EPA Substance Registry System: methyl 3,6-dimethoxy-2-nitrobenzoate(327163-76-8)

Safety Data

• Hazardous Substances Data: 327163-76-8(Hazardous Substances Data)

Upstream product

• 2785-98-0 2,5-dimethoxybenzoic acid 
• 77-78-1 dimethyl sulfate 
• 186581-53-3 diazomethane 
• 89229-48-1 6-hydroxy-3-methoxy-2-nitrobenzoic acid 

Downstream Products

• 208986-13-4 methyl 2-amino-3,6-dimethoxybenzoate 
• 327163-83-7 methyl 3,6-dimethoxy-2-(dimethoxymethyl)-4-(2-propenyl)benzoate 
• 327163-84-8 [2-(dimethoxymethyl)-3,6-dimethoxy-4-(2-propenyl)phenyl]methanol 
• 327163-82-6 1-bromo-2-(dimethoxymethyl)-3,6-dimethoxy-4-(2-propenyl)benzene 
• 327163-80-4 2-bromo-6-hydroxy-3-methoxy-5-(2-propenyl)benzaldehyde 
• 327163-81-5 2-bromo-3,6-dimethoxy-5-(2-propenyl)benzaldehyde 
• 327163-79-1 2-bromo-3-methoxy-6-(2-propenyloxy)benzaldehyde 
• 327163-77-9 methyl 2-bromo-3,6-dimethoxybenzoate 
• 327164-05-6 (2-bromo-3,6-dimethoxyphenyl)methanol 
• 327163-78-0 2-bromo-6-hydroxy-3-methoxybenzaldehyde 
• 85432-87-7 2-bromo-3,6-dimethoxybenzaldehyde 

Relevant articles and documents

ENHANCING AUTOPHAGY OR INCREASING LONGEVITY BY ADMINISTRATION OF UROLITHINS OR PRECURSORS THEREOF

Disclosed are methods, compounds, and compositions useful for increasing autophagy and promoting longevity. The methods, compounds, and compositions relate to urolithins and urolithin precursors and use thereof. Certain urolithins are represented by Formula I, while certain urolithin precursors are represented by Formula IV. The urolithin may be urolithin A, urolithin B, urolithin C, or urolithin D. The urolithin precursor may be ellagic acid or an ellagitannin. The methods include in vivo, ex vivo, and in vitro uses of the compounds and compositions.